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Pre-Treatment Assessment 
1. Obtain a QTc using a standard 12-lead ECG, telemetry, or mobile ECG device 
2. Obtain baseline electrolytes, including calcium, magnesium, and potassium; correct abnormalities 
3. Review the patient’s medications; discontinue any QTc prolonging medications that are not 
necessary 
4. Document high-risk cardiovascular and comorbid conditionsa  
5. Assess and adjust for hepatic and renal dysfunction 
 
Patients taking ONE of the following ONLY: azithromycin, hydroxychloroquine, chloroquine, or 
lopinavir; ritonavir1 
 
Baseline QTc is 500 msec or more OR QTc increases by 60 msec or more after drug initiation 
1. Consider withholding treatment 
2. Correct electrolyte abnormalities 
3. Obtain an on-therapy QTc 2 to 4 hours after the first dose and repeat in 48 and 96 hours 
 
Baseline QTc is 460 to 499 msec (prepubertal patients), 470 to 499 msec (postpubertal males), or 480 to 
499 msec (postpubertal females) 
1. Correct electrolyte abnormalities before drug initiation 
2. Obtain an on-therapy QTc at 48 hours and 96 hours after drug initiation 
 
Baseline QTc is less than 460 msec (prepubertal patients), less than 470 msec (postpubertal males), or 
less than 480 msec (postpubertal females) 
1. Measure an on-therapy QTc at 48 and 96 hours after drug initiation 
2. Correct electrolyte abnormalities once known 
 
Patients taking azithromycin WITH hydroxychloroquine OR chloroquine2 
1. In patients with a baseline QTc more than 500 msec or a history of long QT syndrome, the 
combined use of these agents is relatively contraindicated. 
2. Place patient on telemetry before drug initiation. 
3. Monitor and correct electrolytes at baseline and daily thereafter. 
4. Obtain an ECG 2 to 3 hours after the second dose of antimalarial and then daily thereafter. 
5. If QTc is more than 500 msec or increases by 60 msec or more over baseline, discontinue 
azithromycin and/or decrease dose of the antimalarial. Continue to monitor ECG daily. 
6. If QTc continues to be more than 500 msec or increased by 60 msec or more, consider 
discontinuing the antimalarial. 
 
Immediately discontinue all QT prolonging medications in any patient with Torsade de Pointes 
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aHigh risk conditions include age > 65 years, female patients, bradycardia, heart failure, recent acute coronary syndrome, atrial 
fibrillation, hypertension, heart valve disease, hypocalcemia, hypokalemia, hypomagnesemia, hypothyroidism, systemic 
inflammation (e.g., HIV infection, sepsis, lupus, rheumatoid arthritis), hypothermia, and sleep deprivation 
